Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Saturday 31.10.2020 at 7:00 AM CET
Settings

Settings

Goto Application

1. WO2011008117 - THE USE OF A SIRNA OLIGONUCLEOTIDE

Publication Number WO/2011/008117
Publication Date 20.01.2011
International Application No. PCT/PL2010/000059
International Filing Date 12.07.2010
IPC
C12N 15/113 2010.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/713 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
713Double-stranded nucleic acids or oligonucleotides
CPC
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
C12N 2310/14
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2310Structure or type of the nucleic acid
10Type of nucleic acid
14interfering N.A.
C12N 2320/32
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2320Applications; Uses
30Special therapeutic applications
32Special delivery means, e.g. tissue-specific
Applicants
  • CELON PHARMA Sp. z.o.o. [PL]/[PL] (AllExceptUS)
  • LAMPARSKA-PRZYBYSZ, Monika [PL]/[PL] (UsOnly)
  • GUZENDA, Piotr [PL]/[PL] (UsOnly)
  • HUCZ, Joanna [PL]/[PL] (UsOnly)
  • MAJOREK, Maria [PL]/[PL] (UsOnly)
  • STAŃCZAK, Aleksandra [PL]/[PL] (UsOnly)
  • WIECZOREK, Maciej [PL]/[PL] (UsOnly)
Inventors
  • LAMPARSKA-PRZYBYSZ, Monika
  • GUZENDA, Piotr
  • HUCZ, Joanna
  • MAJOREK, Maria
  • STAŃCZAK, Aleksandra
  • WIECZOREK, Maciej
Agents
  • WITEK, Rafał
Priority Data
PL38851312.07.2009PL
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) THE USE OF A SIRNA OLIGONUCLEOTIDE
(FR) UTILISATION D'OLIGONUCLÉOTIDE D'ARNsi
Abstract
(EN)
We disclose the use of a siRNA oligonucleotide comprising at least 19 nucleotides, complementary to the target mRNA encoding proteins of the WNT/beta-catenin pathway, in the production of a drug for systemic administration in the treatment of cancer.
(FR)
L'invention concerne l'utilisation d'un oligonucléotide d'ARNsi comprenant au moins 19 nucléotides, complémentaire des protéines codant pour l'ARNm cible de la voie WNT/beta-catenine, pour la production d'un médicament destiné à une administration systémique lors du traitement d'un cancer.
Latest bibliographic data on file with the International Bureau